The AML1-ETO, CBFB-MYH11, and PML-RARA oncofusion protein associated AML-subtypes each account for 5%-10% of all AML cases while FUS-ERG fusions are relatively rare (<1%). This evidence concerns the gene CBFB and acute myeloid leukemia.